BofA Downgrades Zoetis (ZTS) to Neutral, Cuts Price Target

Zoetis Inc. (NYSE:ZTS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026.

On December 15, BofA downgraded Zoetis Inc. (NYSE:ZTS) to Neutral from Buy and lowered its price target to $135 from $165.

In other news, on December 5, Zoetis Inc. (NYSE:ZTS) announced that Health Canada approved Portela™ (relfovetmab injection) for the relief of pain linked to osteoarthritis, or OA, in cats. Portela is designed to deliver up to three months of OA pain relief with a single injection. The treatment targets anti-nerve growth factor (NGF), a key driver of OA pain and inflammation.

In a nine-month field trial conducted in Europe, Portela showed it could effectively reduce OA pain and was generally well tolerated. That included cats diagnosed with kidney disease at IRIS stage 1, 2, or 3. Portela is already approved in the European Union, and Zoetis expects to make it commercially available in Canada and the EU in 2026.

Rob Polzer, Ph.D., Executive Vice President and President, Research and Development at Zoetis, made the following comment:

“Health Canada’s approval of Portela marks a significant step forward in managing osteoarthritis-related pain in cats. Thanks to Portela’s long-lasting antibody and its unique binding site to NGF, veterinarians and cat owners in Canada now have a new, innovative way to address osteoarthritis pain. This achievement underscores our ongoing dedication to developing new therapies that improve the health and quality of life for companion animals.”

Zoetis Inc. (NYSE:ZTS) continues to expand its animal health portfolio through lifecycle innovation, geographic expansion, and new product development. Portela adds to the company’s growing lineup of OA pain treatments for cats, alongside Solensia® (frunevetmab injection).

Zoetis Inc. (NYSE:ZTS) is the largest global animal health company, focused on advancing care for animals worldwide.

While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Cash-Rich Stocks to Buy Now and 15 Global Dividend Stocks to Diversify Your Portfolio.

Disclosure: None.